Sign In
Buy RNA
$11.35
-0.110 (-0.96%)
At Close: Jul 31, 2026
Avidity Biosciences Announces Oversubscribed $400 Million Private Placement
07:00am, Thursday, 29'th Feb 2024
Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, Wellingto
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
06:20pm, Wednesday, 28'th Feb 2024
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.88 per share a year ago.
Avidity Biosciences to Participate in Upcoming Investor Conferences
09:00am, Tuesday, 27'th Feb 2024
SAN DIEGO , Feb. 27, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
3 Highly Rated Biotech Stocks to Buy for 300% Gains
06:55am, Monday, 26'th Feb 2024
Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It's also fairly easy to identify such stocks using screener
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 21'st Feb 2024
SAN DIEGO , Feb. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength?
09:56am, Monday, 29'th Jan 2024
Avidity Biosciences, Inc. (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 22'nd Jan 2024
SAN DIEGO , Jan. 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth
08:30am, Friday, 05'th Jan 2024
Avidity plans to initiate global Phase 3 HARBOR ™ trial of AOC 1001 for DM1 mid-2024 Company to report data from all three ongoing clinical programs in 2024 -- AOC 1001 data for DM1 in Q1, AOC 10
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 21'st Dec 2023
SAN DIEGO , Dec. 21, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide C
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
10:32am, Wednesday, 29'th Nov 2023
Avidity (RNA) gains on the expansion of its existing partnership with BMY to discover multiple cardiovascular targets.
Why Is Avidity Biosciences (RNA) Stock Up 15% Today?
10:09am, Tuesday, 28'th Nov 2023
Avidity Biosciences (NASDAQ: RNA ) stock is soaring in early trading after the company disclosed that it had expanded its partnership with a huge drugmaker, Bristol Myers Squibb (NYSE: BMY ). More Abo
Avidity Stock Soars on Collaboration Deal With Bristol Myers
07:43am, Tuesday, 28'th Nov 2023
Bristol Myers has agreed to pay Avidity $60 million in cash and will also purchase about $40 million of Avidity common stock at $7.88 a share.
Avidity Biosciences leaps on Bristol-Myers research tie-up
07:38am, Tuesday, 28'th Nov 2023
Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co (NYSE:BMY). The pact is focused on the discovery, dev
Avidity Biosciences Inc. RNA said Tuesday it's expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal that will see Avidity receive $100 million upfront with the potent
Avidity Biosciences to Participate in Upcoming Investor Conferences
09:00am, Wednesday, 30'th Aug 2023
SAN DIEGO , Aug. 30, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide
